

LÃ©on C Van Kempen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7490059/publications.pdf>

Version: 2024-02-01

114
papers

4,836
citations

81900

39
h-index

102487

66
g-index

117
all docs

117
docs citations

117
times ranked

8747
citing authors

#	ARTICLE	IF	CITATIONS
1	Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. <i>Clinical Lung Cancer</i> , 2022, 23, e104-e115.	2.6	13
2	Persistent biliary hypoxia and lack of regeneration are key mechanisms in the pathogenesis of posttransplant nonanastomotic strictures. <i>Hepatology</i> , 2022, 75, 814-830.	7.3	17
3	CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2. <i>Oncolmmunology</i> , 2022, 11, 2033433.	4.6	9
4	Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort. <i>Diagnostics</i> , 2022, 12, 668.	2.6	17
5	Unmet Needs and Perspectives in Oral Cancer Prevention. <i>Cancers</i> , 2022, 14, 1815.	3.7	14
6	Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study. <i>Lung Cancer</i> , 2022, 167, 1-7.	2.0	11
7	Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling. <i>Clinical Chemistry</i> , 2022, 68, 963-972.	3.2	10
8	Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations. <i>Oncologist</i> , 2021, 26, e1347-e1358.	3.7	28
9	Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer. <i>Canadian Association of Radiologists Journal</i> , 2021, 72, 109-119.	2.0	51
10	ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 3-11.	2.8	26
11	Non-CG methylation and multiple histone profiles associate child abuse with immune and small GTPase dysregulation. <i>Nature Communications</i> , 2021, 12, 1132.	12.8	24
12	Non-small cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy. <i>Histopathology</i> , 2021, 78, 1043-1046.	2.9	2
13	Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing. <i>Nature Communications</i> , 2021, 12, 3361.	12.8	19
14	A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses. <i>Cancers</i> , 2021, 13, 3641.	3.7	11
15	Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors. <i>Molecular Oncology</i> , 2021, 15, 2910-2922.	4.6	23
16	Integrating NGS-derived Mutational Profiling in the Diagnosis of Multiple Lung Adenocarcinomas. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100484.	1.7	2
17	SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment. <i>European Journal of Cancer</i> , 2020, 137, 175-182.	2.8	27
18	Angiosarcomatous transdifferentiation of metastatic melanoma. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 1211-1214.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients. <i>Cancers</i> , 2020, 12, 1222.	3.7	40
20	Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. <i>JCO Precision Oncology</i> , 2020, 4, 520-533.	3.0	9
21	Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation. <i>Lung Cancer</i> , 2020, 146, 358-361.	2.0	37
22	BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells. <i>Cell Death Discovery</i> , 2020, 6, 1.	4.7	59
23	Diagnostic yield of NanoString nCounter FusionPlex profiling in soft tissue tumors. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 318-324.	2.8	12
24	Imaging-Based Surrogate Markers of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma: A Local Perspective. <i>Canadian Association of Radiologists Journal</i> , 2020, 71, 208-216.	2.0	2
25	Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-“Small-Cell Lung Cancer With Rare or Complex Mutational Profiles. <i>JCO Precision Oncology</i> , 2020, 4, 393-410.	3.0	32
26	Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. <i>BMC Cancer</i> , 2020, 20, 291.	2.6	20
27	Abstract PO-45: Robust detection of translocations in lymphoma FFPE samples using Targeted Locus Capture-based sequencing. , 2020, , .		2
28	Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy. <i>Molecular Cancer Research</i> , 2019, 17, 2422-2431.	3.4	3
29	An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma. <i>European Journal of Cancer</i> , 2019, 114, 1-7.	2.8	38
30	Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 673-680.	2.8	24
31	Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non-“Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 352-365.	2.8	14
32	Abstract 1398: Modeling of drug-protein interactions to support clinical decision making for therapy-resistantEGFRorALK-positive non-small cell lung carcinoma. , 2019, , .		1
33	Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1417-1422.	1.2	92
34	Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e161-e163.	1.1	9
35	eIF4E-Binding Proteins 1 and 2 Limit Macrophage Anti-Inflammatory Responses through Translational Repression of IL-10 and Cyclooxygenase-2. <i>Journal of Immunology</i> , 2018, 200, 4102-4116.	0.8	14
36	Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma. <i>Cell Reports</i> , 2018, 22, 3206-3216.	6.4	19

#	ARTICLE	IF	CITATIONS
37	P2.01-04 Reducing Time to Molecular Diagnosis for Advanced NSCLC in the Context of a Reference Testing Center. <i>Journal of Thoracic Oncology</i> , 2018, 13, S666.	1.1	0
38	KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e249-e251.	1.1	28
39	Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2018, 10, 459.	3.7	16
40	Expression map of 78 brain-expressed mouse orphan GPCRs provides a translational resource for neuropsychiatric research. <i>Communications Biology</i> , 2018, 1, 102.	4.4	49
41	MBRS-36. IDENTIFICATION OF TWO PROTEIN-SIGNALING STATES DELINEATING TRANSCRIPTIONALLY HETEROGENEOUS HUMAN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i136-i136.	1.2	0
42	The Protozoan Parasite <i>Toxoplasma gondii</i> Selectively Reprograms the Host Cell Translatome. <i>Infection and Immunity</i> , 2018, 86, .	2.2	22
43	Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP).. <i>Journal of Clinical Oncology</i> , 2018, 36, 185-185.	1.6	2
44	Multi-platform characterization of cutaneous melanoma from patients treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15071-e15071.	1.6	0
45	Association of a History of Child Abuse With Impaired Myelination in the Anterior Cingulate Cortex: Convergent Epigenetic, Transcriptional, and Morphological Evidence. <i>American Journal of Psychiatry</i> , 2017, 174, 1185-1194.	7.2	146
46	Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. , 2017, 5, 83.		46
47	Abstract CT098: Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies. , 2017, , .		2
48	Impact of the epigenetic modulator BORIS on sensitivity of melanoma cells to UV-induced DNA damage.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21077-e21077.	1.6	0
49	Abstract 754: Treatment decision-making of rareERBB2(HER2) mutations in lung cancer; a role for multidisciplinary molecular tumor boards. , 2017, , .		0
50	Abstract 1764: Accurate and reproducible detection of fusions and exon skipping events in NSCLC-derived samples using a comprehensive, targeted RNA-Seq system across multiple laboratories. , 2017, , .		0
51	The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. <i>Science Translational Medicine</i> , 2016, 8, 369ra177.	12.4	33
52	L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma. <i>Pathology and Oncology Research</i> , 2016, 22, 863-868.	1.9	31
53	Analysis of the Tumor Microenvironment Transcriptome via NanoString mRNA and miRNA Expression Profiling. <i>Methods in Molecular Biology</i> , 2016, 1458, 291-310.	0.9	11
54	p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib. <i>European Journal of Cancer</i> , 2016, 55, 98-110.	2.8	48

#	ARTICLE	IF	CITATIONS
55	Biallelic <i>NTHL1</i> Mutations in a Woman with Multiple Primary Tumors. <i>New England Journal of Medicine</i> , 2015, 373, 1985-1986.	27.0	75
56	SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma. <i>British Journal of Cancer</i> , 2015, 113, 91-98.	6.4	26
57	The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1368-1376.	0.7	24
58	Molecular pathology of cutaneous melanoma. <i>Melanoma Management</i> , 2014, 1, 151-164.	0.5	4
59	Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. <i>Gut</i> , 2014, 63, 674-685.	12.1	221
60	The validity of circulating microRNAs in oncology: Five years of challenges and contradictions. <i>Molecular Oncology</i> , 2014, 8, 819-829.	4.6	149
61	Critical appraisal of quantitative PCR results in colorectal cancer research: Can we rely on published qPCR results?. <i>Molecular Oncology</i> , 2014, 8, 813-818.	4.6	49
62	Collagen type III alpha 1 polymorphism (rs1800255, COL3A1 2209 G>A) assessed with high-resolution melting analysis is not associated with pelvic organ prolapse in the Dutch population. <i>International Urogynecology Journal</i> , 2014, 25, 1237-1242.	1.4	13
63	From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting. <i>Molecular Oncology</i> , 2014, 8, 781-782.	4.6	3
64	A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9066-9066.	1.6	4
65	Molecular testing in Cutaneous Melanoma. , 2014, , 363-374.		1
66	Abstract 3710: The role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to Vemurafenib in melanoma. , 2014, , .		0
67	A Possible Role for MicroRNA-141 Down-Regulation in Sunitinib Resistant Metastatic Clear Cell Renal Cell Carcinoma Through Induction of Epithelial-to-Mesenchymal Transition and Hypoxia Resistance. <i>Journal of Urology</i> , 2013, 189, 1930-1938.	0.4	61
68	L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1142-1150.	6.3	185
69	Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients. <i>British Journal of Cancer</i> , 2013, 108, 1641-1647.	6.4	20
70	Modulation of Activated Leukocyte Cell Adhesion Molecule-mediated Invasion Triggers an Innate Immune Gene Response in Melanoma. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1462-1470.	0.7	10
71	Cytology of the vulva: feasibility and preliminary results of a new brush. <i>British Journal of Cancer</i> , 2012, 106, 269-273.	6.4	14
72	A systematic review of clinical studies on hereditary factors in pelvic organ prolapse. <i>International Urogynecology Journal</i> , 2012, 23, 1327-1336.	1.4	74

#	ARTICLE	IF	CITATIONS
73	Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 441-448.	2.8	49
74	EORTC Melanoma Group achievements. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 112-119.	2.2	0
75	Pelvic organ prolapse and collagen-associated disorders. <i>International Urogynecology Journal</i> , 2012, 23, 313-319.	1.4	69
76	The dual role of the X-linked FoxP3 gene in human cancers. <i>Molecular Oncology</i> , 2011, 5, 156-163.	4.6	21
77	P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. <i>Nature Communications</i> , 2011, 2, 555.	12.8	152
78	GLI2 and MÎMITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 932-943.	3.3	71
79	Identification of Six Loci Associated With Pelvic Organ Prolapse Using Genome-Wide Association Analysis. <i>Obstetrics and Gynecology</i> , 2011, 118, 1345-1353.	2.4	47
80	Efficient TGF-Î²/SMAD signaling in human melanoma cells associated with high c-SKI/SnoN expression. <i>Molecular Cancer</i> , 2011, 10, 2.	19.2	46
81	Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma. <i>Modern Pathology</i> , 2011, 24, 297-305.	5.5	139
82	TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome. <i>British Journal of Cancer</i> , 2011, 105, 1726-1732.	6.4	45
83	Abstract 4835: Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survival. , 2011, , .		0
84	Keratinocytes drive melanoma invasion in a reconstructed skin model. <i>Melanoma Research</i> , 2010, 20, 372-380.	1.2	31
85	"Differentiated-Type Vulval Intraepithelial Neoplasia Has a High-Risk Association With Vulval Squamous Cell Carcinoma". <i>International Journal of Gynecological Cancer</i> , 2010, 20, 194.	2.5	6
86	Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 693-703.	2.8	9
87	Natural Killer Cells and HLA-G Expression in the Basal Decidua of Human Placenta Adhesiva. <i>Placenta</i> , 2010, 31, 1078-1084.	1.5	7
88	Soluble adhesion molecules in human cancers: Sources and fates. <i>European Journal of Cell Biology</i> , 2010, 89, 415-427.	3.6	43
89	Specific intraepithelial localization of mast cells in differentiated vulvar intraepithelial neoplasia and its possible contribution to vulvar squamous cell carcinoma development. <i>Histopathology</i> , 2010, 57, 351-362.	2.9	6
90	GLI2-Mediated Melanoma Invasion and Metastasis. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1148-1159.	6.3	149

#	ARTICLE	IF	CITATIONS
91	Epidemiology of Extracutaneous Melanoma in the Netherlands. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1453-1459.	2.5	32
92	Stromal regulation of vessel stability by MMP14 and TGF β 2. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 317-332.	2.4	82
93	The biology of melanoma prognostic factors. <i>Discovery Medicine</i> , 2010, 10, 87-93.	0.5	10
94	The Etiologic Role of HPV in Vulvar Squamous Cell Carcinoma Fine Tuned. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2061-2067.	2.5	123
95	Reliable Identification of the Type III Collagen Gene Polymorphism rs1800255 with the Use of High Resolution Melting Analysis. <i>Laboratory Medicine</i> , 2009, 40, 604-606.	1.2	1
96	COL3A1 2209G>A is a predictor of pelvic organ prolapse. <i>International Urogynecology Journal</i> , 2009, 20, 1113-1118.	1.4	49
97	Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. <i>International Journal of Cancer</i> , 2008, 122, 1019-1029.	5.1	63
98	Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. <i>International Journal of Cancer</i> , 2008, 123, 2354-2361.	5.1	76
99	Semaphorin 3E Expression Correlates Inversely with Plexin D1 During Tumor Progression. <i>American Journal of Pathology</i> , 2008, 173, 1873-1881.	3.8	48
100	Attenuation of Melanoma Invasion by a Secreted Variant of Activated Leukocyte Cell Adhesion Molecule. <i>Cancer Research</i> , 2008, 68, 3671-3679.	0.9	61
101	Reactive oxygen species in melanoma and its therapeutic implications. <i>Melanoma Research</i> , 2007, 17, 400-409.	1.2	124
102	Loss of membranous Ep-CAM in budding colorectal carcinoma cells. <i>Modern Pathology</i> , 2007, 20, 221-232.	5.5	109
103	Melanoma progression in a changing environment. <i>European Journal of Cell Biology</i> , 2007, 86, 65-67.	3.6	13
104	Distinct phenotypic changes between the superficial and deep component of giant congenital melanocytic naevi: a rationale for curettage. <i>British Journal of Dermatology</i> , 2006, 154, 485-492.	1.5	47
105	Tumours can adapt to anti-angiogenic therapy depending on the stromal context: Lessons from endothelial cell biology. <i>European Journal of Cell Biology</i> , 2006, 85, 61-68.	3.6	27
106	Activated leukocyte cell adhesion molecule (ALCAM/CD166): Signaling at the divide of melanoma cell clustering and cell migration?. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 223-236.	5.9	97
107	Truncation of Activated Leukocyte Cell Adhesion Molecule: A Gateway to Melanoma Metastasis. <i>Journal of Investigative Dermatology</i> , 2004, 122, 1293-1301.	0.7	53
108	The tumor microenvironment: a critical determinant of neoplastic evolution. <i>European Journal of Cell Biology</i> , 2003, 82, 539-548.	3.6	211

#	ARTICLE	IF	CITATIONS
109	MMP9 potentiates pulmonary metastasis formation. <i>Cancer Cell</i> , 2002, 2, 251-252.	16.8	152
110	Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. <i>Differentiation</i> , 2002, 70, 610-623.	1.9	73
111	BIBX1382BS, but Not AG1478 or PD153035, Inhibits the ErbB Kinases at Different Concentrations in Intact Cells. <i>Biochemical and Biophysical Research Communications</i> , 2001, 281, 25-31.	2.1	39
112	Molecular Basis for the Homophilic Activated Leukocyte Cell Adhesion Molecule (ALCAM)-ALCAM Interaction. <i>Journal of Biological Chemistry</i> , 2001, 276, 25783-25790.	3.4	137
113	Activated Leukocyte Cell Adhesion Molecule/CD166, a Marker of Tumor Progression in Primary Malignant Melanoma of the Skin. <i>American Journal of Pathology</i> , 2000, 156, 769-774.	3.8	192
114	Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice. <i>Critical Care Medicine</i> , 1998, 26, 1244-1250.	0.9	18